MX2020005336A - Analogos de d-serina deuterados y usos de los mismos. - Google Patents

Analogos de d-serina deuterados y usos de los mismos.

Info

Publication number
MX2020005336A
MX2020005336A MX2020005336A MX2020005336A MX2020005336A MX 2020005336 A MX2020005336 A MX 2020005336A MX 2020005336 A MX2020005336 A MX 2020005336A MX 2020005336 A MX2020005336 A MX 2020005336A MX 2020005336 A MX2020005336 A MX 2020005336A
Authority
MX
Mexico
Prior art keywords
serine
deuterated analogs
deuterated
analogs
prodrugs
Prior art date
Application number
MX2020005336A
Other languages
English (en)
Inventor
Dario Doller
Julie F Liu
Roger D Tung
Christopher L Brummel
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2020005336A publication Critical patent/MX2020005336A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta divulgación se refiere a la D-serina deuterada, a las sales farmacéuticamente aceptables de la misma, a los análogos y profármacos de la misma, a las composiciones farmacéuticas de la misma, y a los métodos de uso.
MX2020005336A 2017-11-22 2018-11-21 Analogos de d-serina deuterados y usos de los mismos. MX2020005336A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762590109P 2017-11-22 2017-11-22
US201862636081P 2018-02-27 2018-02-27
US201862636427P 2018-02-28 2018-02-28
US201862755157P 2018-11-02 2018-11-02
PCT/US2018/062263 WO2019104179A1 (en) 2017-11-22 2018-11-21 Deuterated analogs of d-serine and uses thereof

Publications (1)

Publication Number Publication Date
MX2020005336A true MX2020005336A (es) 2020-08-13

Family

ID=64755715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005336A MX2020005336A (es) 2017-11-22 2018-11-21 Analogos de d-serina deuterados y usos de los mismos.

Country Status (12)

Country Link
US (2) US20200368193A1 (es)
EP (1) EP3713557A1 (es)
JP (1) JP2023123476A (es)
KR (1) KR20200103662A (es)
CN (1) CN111491629A (es)
AU (1) AU2018371784A1 (es)
BR (1) BR112020010156A2 (es)
CA (1) CA3082834A1 (es)
IL (1) IL274585A (es)
MX (1) MX2020005336A (es)
TW (1) TW201924668A (es)
WO (1) WO2019104179A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
RU2738873C2 (ru) * 2018-12-29 2020-12-17 Общество С Ограниченной Ответственностью "Сольвекс" (Ооо "Сольвекс") Препарат для магнитно-резонансной томографии, содержащий дейтерированный саркозин, и способ диагностики с использованием этого препарата
US20220169595A1 (en) * 2019-04-03 2022-06-02 Concert Pharmaceuticals, Inc. Processes for the preparation of deuterated d-serine
US20220218641A1 (en) * 2019-05-30 2022-07-14 Concert Pharmaceuticals, Inc. Methods of treatment with deuterated analogs of d-serine
JP2023507584A (ja) * 2019-12-19 2023-02-24 イントラ－セルラー・セラピーズ・インコーポレイテッド 統合失調症処置方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582931A (en) * 1984-12-24 1986-04-15 Merck & Co., Inc. Preparation of 2-Deutero-D-serine
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
WO1997020552A1 (en) 1995-12-07 1997-06-12 Albert Einstein College Of Medicine Of Yeshiva University Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
PT1073432E (pt) * 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6258605B1 (en) 1999-03-26 2001-07-10 Neo Gen Screening, Inc. Clinical method for the genetic screening of newborns using tandem mass spectrometry
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ES2193921T3 (es) 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
ATE282428T1 (de) 2001-05-03 2004-12-15 Hoffmann La Roche Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
IL154318A (en) * 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
CN101076319A (zh) 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
AU2006235400A1 (en) 2005-04-11 2006-10-19 Yale University Method of treating schizophrenia prodrome
AU2006299424A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
US9040581B1 (en) 2013-02-21 2015-05-26 The Florida State University Research Foundation, Inc. Methods of treatment using D-serine
CA2913454C (en) 2013-05-28 2021-09-07 Sarah Herzog Memorial Hospital-Ezrath Nashim Autoimmune-induced glutamatergic receptor dysfunction methods and treatments
WO2014205074A2 (en) 2013-06-18 2014-12-24 The Trustees Of Columbia University In The City Of New York Devices, compositions and methods for imaging with raman scattering
WO2015160470A2 (en) * 2014-03-20 2015-10-22 The Trustees Of Princeton University Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease
GB201521903D0 (en) 2015-12-11 2016-01-27 Electrophoretics Ltd Isorbaric mass labels
CN109564207B (zh) 2016-06-02 2021-07-02 梅塔博隆股份有限公司 用于检测和定量代谢物的质谱方法
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof

Also Published As

Publication number Publication date
IL274585A (en) 2020-06-30
US20200368193A1 (en) 2020-11-26
KR20200103662A (ko) 2020-09-02
JP2021504326A (ja) 2021-02-15
CA3082834A1 (en) 2019-05-31
WO2019104179A4 (en) 2019-08-01
CN111491629A (zh) 2020-08-04
US20200390732A1 (en) 2020-12-17
JP2023123476A (ja) 2023-09-05
WO2019104179A1 (en) 2019-05-31
AU2018371784A1 (en) 2020-05-28
US20190328692A1 (en) 2019-10-31
TW201924668A (zh) 2019-07-01
US10668036B2 (en) 2020-06-02
EP3713557A1 (en) 2020-09-30
BR112020010156A2 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
MX2020005336A (es) Analogos de d-serina deuterados y usos de los mismos.
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
MX2022005610A (es) Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
PH12018500065A1 (en) Oxysterols and methods of use thereof
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018500071B1 (en) Plinabulin compositions
MY197698A (en) Oxysterols and methods of use thereof
PH12018500047A1 (en) Notch pathway signaling inhibitor compounds
PH12017500095A1 (en) Imidazopyridazine compounds
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
CY1123469T1 (el) Σχηματα δοσολογιας του melflufen για καρκινο
BR112018016032A2 (pt) composto, composição farmacêutica e método para melhorar um distúrbio
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
IN2013CH04314A (es)
IN2013MU03428A (es)
EA202091263A1 (ru) Дейтерированные аналоги d-серина и их применение
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MY195679A (en) Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders
NZ736342A (en) Use of potassium hydroxide in the treatment of actinic keratosis